Gland Pharma Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2v7pb32gf3gpbceknq5mt6sz.pdf

Key Takeaways


Cenexi Acquisition: The Quarter’s Distortion

Srinivas Sadu: "I think we can't comment, it is too early, maybe at the end of next year we will be better off, so currently we want to stick to that number."

Base Business Margins: Strong Today, Softer Tomorrow

Srinivas Sadu: "I still consider 30%–32% could be the targeted EBITDA margin because Enoxa, compared to low-margin products, will start to gain from the next quarter and subsequent quarters."

US Market: Stability Returns

Srinivas Sadu: "I would say the drop has stopped; earlier, every quarter, you used to see a fall in prices. At least that is not happening now. So, it is basically a little stable."

Cenexi Turnaround: Capex, Tech Transfer, and a Long Fuse


Rest of World and Other Markets: Patchy, with a China Option

Srinivas Sadu: "It is more of the timing which quarter it goes than anything else and of course the pricing of Enoxa."

Capital Allocation and Pipeline

Srinivas Sadu: "We are still staying away from giving the guidance, but the idea is to give steady growth quarter-on-quarter. That is how we are seeing the next few quarters."

Guidance & Commitments

CommitmentSpecificsTimeline
Cenexi quarterly revenue run-rate€50–55 mn per full quarterFrom Q3 FY24 onwards
Cenexi annual EBITDA margin10%–11%FY24, normalising after shutdown
Base business ex-Cenexi EBITDA margin30%–32%From Q3 FY24, as Enoxaparin volumes return
Cenexi medium-term EBITDA margin13%–15%Medium-term; too early to commit to higher
Cenexi capex programme€30–35 mn (of €60 mn total investment)Over next 18 months
Cenexi tech-transfer commercialisationVolumes from ~25 projects beginEnd of next year / beginning of 2025
Base business capex FY24₹250–300 croreFY24
Base business capex FY25~₹300 croreFY25
Complex product submissionsAt least 3 products ready for filingNext 5–6 months
China second product launchOne more product launchedNext quarter
US base business growthSteady sequential improvement from ~₹1,000 crore baseNext few quarters

Key Metrics

MetricQ2 FY24
Revenue₹1,373.4 cr, +32% YoY and +14% QoQ
Gross margin62%, up from 50% in Q2 FY23
EBITDA₹320.5 cr, +8% YoY
EBITDA margin23%, vs 28% in Q2 FY23
Base business (Ex-Cenexi) EBITDA margin34%, up from 28% in Q2 FY23
Net profit₹194.1 cr, -20% YoY
PAT margin14%
US market revenue growth+22% QoQ, +9% YoY
Core markets revenue share74% of revenue, up from 72% in Q2 FY23
India market revenue growth+21% YoY
Rest of world markets revenue share19% of revenue, -9% QoQ
R&D expense₹35.1 cr, 3% of operating revenue (3.5% Ex-Cenexi)
ANDAs filed in the quarter1 filed, 5 approved
Cenexi revenue₹358.8 cr for two months of operations
Cenexi EBITDAnegative ₹26.8 cr
Cash and equivalents (group)₹2,262.7 cr, net cash position ₹1,950 cr
Average cash conversion cycle196 days, improved from 226 days in H1 FY23